Name | Title | Contact Details |
---|
American Society of Plastic Surgeons is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SunLink Health Systems, Inc. currently operates seven community hospitals and related nursing home and home care businesses in the Southeast and Midwest, and its specialty pharmacy business, SunLink Scripts Rx, in Louisiana and Georgia. Each SunLink hospital is the only hospital in its community. SunLink's operating strategy is to link patients' needs with dedicated physicians and health professionals to deliver quality, efficient medical care and healthcare products and services in each area it serves. For additional information on SunLink Health Systems, Inc.
As the nation’s leading community oncology alliance, RainTree Oncology Services assists our member practices in achieving better and more cost effective treatment of oncology patients while creating new streams of revenue for community oncology practices through. Creating a unique aggregated data compilation and analytic platform allowing RainTree members to develop and evaluate care pathways to improve patient care and outcomes while reducing costs to the health care system; and Developing commercial relationships accelerating innovative oncology treatments and payer arrangements while optimizing oncology patient care and advancing the science of oncology.
TheraMatrix is a Pontiac, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.